C
Craig S. Rosenfeld
Researcher at University of Pittsburgh
Publications - 29
Citations - 2020
Craig S. Rosenfeld is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Bone marrow & Myelodysplastic syndromes. The author has an hindex of 13, co-authored 29 publications receiving 1907 citations.
Papers
More filters
Journal ArticleDOI
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Hagop Kantarjian,J. Issa,Craig S. Rosenfeld,John M. Bennett,Maher Albitar,John DiPersio,Virginia Klimek,James Slack,Carlos de Castro,Farhad Ravandi,Richard Helmer,Lanlan Shen,Stephen D. Nimer,Richard Leavitt,Azra Raza,Hussain Saba +15 more
TL;DR: Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy.
Journal Article
Bone marrow transplant-associated thrombotic microangiopathy: a case series.
TL;DR: Results indicate that BMT-TM is common following allogeneic-BMT and the outcome is dependent on the grade, with those with grade 1-2 doing well and those with grades 3-4 doing well.
Journal Article
Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
Donna Przepiorka,S Shapiro,Terry L. Schwinghammer,Elana J. Bloom,Craig S. Rosenfeld,Richard K. Shadduck,Raman Venkataramanan +6 more
TL;DR: Although the combination of CSA and MP in this dosing schedule was active in preventing acute GVHD, nephrotoxicity remained a problem, and outcome was limited by the inability to achieve the target CSA trough concentration in a substantial proportion of patients.
Journal ArticleDOI
First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).
Hussain I. Saba,Craig S. Rosenfeld,Jean Pierre J. Issa,John F. DiPersio,Azra Raza,Virginia M. Klimek,James L. Slack,Carlos M. de Castro,Karl Mettinger,Hagop M. Kantarjian +9 more
TL;DR: DAC appears a promising therapy for MDS with manageable toxicity, and Kaplan Meier (KM) curves for time to AML progression or death showed early and clinically meaningful separation in favor of DAC in all patients (intent to treat; ITT), Int-2/High Risk, and High Risk patients.
Journal ArticleDOI
Flow cytometric measurement of antiplatelet antibodies.
TL;DR: Measurement of platelet surface immunoglobulin with this flow cytometric technic helps differentiate immune from nonimmune thrombocytopenia.